Ceretas LtdASX: CTS

First Patient Enrolled in Phase 2 CERE-CALM Clinical Trial

· Issued by Ceretas Ltd via ASX

Filed with ASX · · 6 pages · English

Summary by 6ix AI

The trial is designed as a randomized, double-blind, sham-controlled study targeting a specific number of participants to assess treatment efficacy, safety, and tolerability. Patient recruitment is currently underway at multiple clinical sites in Australia, with the trial expected to be fully funded and completed within a specified timeframe.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

On 6ix: 6ix.com/news/first-patient-enrolled-in-phase-2-cere-calm-clinical-trial-1

Release

ASX Announcement First Patient Enrolled in Phase 2 CERE-CALM Clinical Trial § First patient enrolled in Phase 2 CERE-CALM trial, marking an important milestone in the development of Ceretas’ non-invasive therapeutic ultrasound platform § CERE-CALM is evaluating focused ultrasound...

Ceretas Ltd on 6ix

Earlier from Ceretas

Later from Ceretas

All Ceretas news releases